SMTL ID : 7ok3.1

Crystal Structure of KRasG13C in Complex with Nucleotide-based Covalent Inhibitor edaGDP

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.60 Å

Oligo State

monomer

Ligands

1 x VJ8: edaGDP(Covalent)

VJ8.1: 21 residues within 4Å: Chain A: A.12, G.13, C.14, V.15, G.16, K.17, S.18, A.19, F.29, V.30, D.31, E.32, Y.33, A.60, N.117, K.118, D.120, L.121, S.146, A.147, K.148 23 PLIP interactions: 23 interactions with chain A Hydrogen bonds: A:A.12, A:C.14, A:V.15, A:G.16, A:G.16, A:K.17, A:S.18, A:S.18, A:A.19, A:D.31, A:Y.33, A:N.117, A:K.118, A:K.118, A:S.146, A:A.147, A:K.148 Water bridges: A:K.17 Salt bridges: A:K.17, A:D.120 pi-Stacking: A:F.29, A:F.29 pi-Cation interactions: A:K.118

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Goebel, L. et al., Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. Elife (2023)

Release Date

2022-08-03

Peptides

Isoform 2B of GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Isoform 2B of GTPase KRas

Related Entries With Identical Sequence